Smoking and mental health - NCSCT

Smoking and mental health
26 Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation
and reduction in schizophrenia: systematic review and meta-analysis. British Journal of
Psychiatry 2010;196:346.
27 Yousefi M, Folsom T, Fatemi H. A review of the efficacy and tolerability of varenicline in
smoking cessation studies in subjects with schizophrenia. Journal of Addiction Research
and Therapy 2011;S4:3045.
28 McEwen A, West R, McRobbie H. Effectiveness of specialist group treatment for smoking
cessation vs. one-to-one treatment in primary care. Addictive Behaviors 2006;31:1650–60.
29 George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical
antipsychotic medications for smoking cessation in schizophrenia. American Journal of
Psychiatry 2000;157:1835–42.
30 Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking
cessation intervention among people with a psychotic disorder. American Journal of
Psychiatry 2006;163:1934–42.
31 Campion J, Hewitt J, Shiers D, Taylor D (2010) Pharmacy guidance on smoking and
mental health. Forum for Mental Health in Primary Care. www.rcpsych.ac.uk/pdf/
Pharmacy_%20guidance%20for%20smoking%20and%20mental%20health%20Feb
%202010.pdf [Accessed 20 February 2013]
32 Weiser M, Reichenberg A, Grotto I. Higher rates of cigarette smoking in male adolescents
before the onset of schizophrenia: a historical-prospective cohort study. American Journal
of Psychiatry 2004;161:1219–23.
33 Williams JM, Ziedonis DM, Abanyie F. Increased nicotine and cotinine levels in smokers
with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophrenia
Research 2005;79:323–35.
34 Williams JM, Ziedonis DM, Foulds J. A case series of nicotine nasal spray in the treatment
of tobacco dependence among patients with schizophrenia. Hospital and Community
Psychiatry 2004;55:1064–6.
35 Evins A, Mays V, Rigotti N, et al. A pilot trial of bupropion added to cognitive behavioural
therapy for smoking cessation in schizophrenia. Nicotine and Tobacco Research
2001;3:397–403.
36 Evins A, Cather C, Deckersbach T, et al. Double-blind, placebo-controlled trial of
bupropion sustained-release for smoking cessation in schizophrenia. Journal of Clinical
Psychopharmacology 2005;25:218–25.
37 George T, Vessicchio J, Termine A, et al. A Placebo controlled trial of bupropion for
smoking cessation in schizophrenia. Biological Psychiatry 2002;52:53–61.
38 Evins A, Cather C, Culhane M, et al. A 12-week double-blind, placebo-controlled study of
bupropion SR added to high-dose dual nicotine replacement therapy for smoking
cessation or reduction in schizophrenia. Journal of Clinical Psychopharmacology
2007;27:380–6.
39 George T, Vessicchio J, Sacco K, et al. A placebo-controlled trial of bupropion combined
with nicotine patch for smoking cessation in schizophrenia. Biological Psychiatry
2008;63:1092–6.
40 Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a
cohort study based on data from the General Practice Research Database. British Medical
Journal 2009;339:b3805.
41 Williams J, Anthenelli R, Morris C, et al. A randomised, double-blind, placebo-controlled
study evaluating the safety and efficacy of varenicline for smoking cessation in patients
with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry
2012;73:654–60.
106 © Royal College of Physicians 2013